Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.

Author: FongK-W, GohC, KhooM-L, LeongS-S, LimD, LuP, MachinD, SeeA, SooK-C, TaiB-C, TanE-H, TanT, WeeJ

Paper Details 
Original Abstract of the Article :
We compared concurrent combination chemotherapy and radiotherapy with surgery and adjuvant radiotherapy in patients with stage III/IV nonmetastatic squamous cell head and neck cancer. Patients with non-nasopharyngeal and nonsalivary resectable squamous cell head and neck cancer were randomised to re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361563/

データ提供:米国国立医学図書館(NLM)

Surgical vs. Concurrent Chemoradiotherapy in Head and Neck Cancer: A Comparative Analysis

The field of [head and neck cancer treatment] strives to find the most effective and minimally invasive approaches for managing this complex disease. This study compares two treatment strategies for stage III/IV non-metastatic squamous cell head and neck cancer: surgery followed by adjuvant radiotherapy versus concurrent combination chemotherapy and radiotherapy.

A Head-to-Head Comparison of Treatment Strategies

The study randomized patients to receive either surgery followed by adjuvant radiotherapy or concurrent combination chemotherapy and radiotherapy. At a median follow-up of 6 years, the 3-year disease-free survival rate was similar between the two groups. However, the study found a higher organ preservation rate, or avoidance of surgery to the primary site, in the concurrent chemoradiotherapy group, particularly for patients with laryngeal/hypopharyngeal disease. This finding suggests that concurrent chemoradiotherapy may offer a less invasive approach to treating certain types of head and neck cancer while achieving comparable survival rates.

Navigating Treatment Decisions

This study provides valuable insights into the decision-making process for treating advanced head and neck cancer. It highlights the potential benefits of concurrent chemoradiotherapy, particularly in terms of organ preservation, while acknowledging that the choice of treatment should ultimately be tailored to individual patient characteristics and the specific type of cancer.

Dr.Camel's Conclusion

Just as a camel navigates diverse landscapes, this research explores the effectiveness of two distinct treatment approaches for head and neck cancer. The findings suggest that concurrent chemoradiotherapy may offer a less invasive alternative for certain types of cancer, potentially minimizing the need for extensive surgery while achieving similar outcomes. However, individual patient needs and the specific type of cancer remain crucial considerations in determining the best treatment strategy.
Date :
  1. Date Completed 2005-09-27
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

16012523

DOI: Digital Object Identifier

PMC2361563

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.